https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Can biomarkers help us hit targets in difficult-to-treat asthma? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34558 Wed 10 Nov 2021 15:14:18 AEDT ]]> International variation in severe exacerbation rates in patients with severe asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:56095 Tue 30 Jul 2024 17:17:51 AEST ]]> Characterization of severe asthma worldwide: data from the International Severe Asthma Registry https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38580 Tue 09 Nov 2021 15:45:37 AEDT ]]> Potential severe asthma hidden in UK primary care https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48386 2-agonist add-ons (54.1 vs 39.8%), and experienced significantly (P < .001) more exacerbations per year (median, 3 vs 2/y), worse asthma control, and worse lung function (% predicted postbronchodilator FEV1/forced vital capacity, 0.69 vs 0.72) versus nonreferred patients. Confirmed patients with severe asthma (ie, UK patients in the International Severe Asthma Registry) were younger (51 vs 65 years; P < .001), and significantly (P < .001) more likely to have uncontrolled asthma (91.4% vs 62.5%), a higher exacerbation rate (4/y [initial assessment] vs 3/y), use inhaled corticosteroid/long-acting β₂-agonist add-ons (67.7% vs 54.1%), and have nasal polyposis (24.2% vs 6.8) than referred patients with PSA. Conclusions: Large numbers of patients with PSA in the United Kingdom are underrecognized in primary care. These patients would benefit from a more systematic assessment in primary care and possible specialist referral.]]> Thu 16 Mar 2023 08:32:39 AEDT ]]> After asthma: redefining airways diseases https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43034 Mon 12 Sep 2022 11:49:26 AEST ]]> Moving towards a Treatable Traits model of care for the management of obstructive airways diseases https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48632 Fri 24 Mar 2023 10:57:01 AEDT ]]> Randomised controlled trial for the titration of oral corticosteroids using markers of inflammation in severe asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53104 Fri 17 Nov 2023 11:38:03 AEDT ]]> Balancing the needs of the many and the few: where next for adult asthma guidelines? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49414 Fri 12 May 2023 15:02:09 AEST ]]> The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46066 Fri 11 Nov 2022 14:45:17 AEDT ]]> Development of the international severe asthma registry (ISAR): a modified Delphi study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48167 Fri 10 Mar 2023 18:24:35 AEDT ]]>